Down 9.4% today, more than its biotech peers' 2.4%; no story names it yet.
Down 18% since Oct 28
Down 18% so far from Oct 28 to Nov 2.
ABCL's Quality Score fell 2 points on Mon, Nov 2, to 7.
Follow ABCL's trial news. Pro members can get an alert when AbCellera Biologics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| The company | Sales up 101% on the year |
| Latest filing | 424B5, Aug 13 |
TodayNo story names it yet.
Wed Nov 11: Stifel Healthcare Conference 2026Investor conference · date confirmed.
1 more date ahead: the conference, for Pro members.
After its last 4 reports it closed -2.5% on average, higher 1 of 4 times.
$120M in cash
Director Michael R Hayden bought 53,613 shares on Aug 24. 5 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Averagefor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means
Well below its recent run. ABCL scores 7 today, against a median of 11 over its last 20 recorded sessions.
ABCL is #50 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 50 |
Share count against a year before: ABCL +2.4%, IMNM +30%, XENE +26%, ZYME -3.1%.
Reports Mon Nov 9, after the close (in 7 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
ABCL's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“Last quarter we completed enrollment for the Phase 2 study of ABCL635, and we expect to announce top-line data very soon,” said Carl Hansen, Ph.D., founder and CEO of AbCellera.”
From its results filing (SEC filing · Aug 5)
Sales fell 20% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 2.6% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 5, 2026 | -2.2% | +10.3% | +74.9% |
| May 11, 2026 | -9.3% | -5.7% | -20.8% |
| Feb 24, 2026 | +4.3% | -0.9% | +15.2% |
Sales grew in four of the last six years, to $75.1M in 2025. It made a profit in three of the seven years.
3 insiders bought $1.6M across 5 filings in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
“The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products.”
ABCL scores 7 today, which Breakaway calls Average. It is #50 of 291 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 18% so far from Oct 28 to Nov 2. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ABCL scores 7 today, which Breakaway calls Average (6 to 10). That is #50 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ABCL's 7.
3 insiders bought $1.6M across 5 filings in the last 6 months. No open-market sales on record. The newest is Michael R. Hayden, Director, who bought $570K on Aug 24. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.